To examine the association between VEGF pathway inhibitors and therapy-induced hypertension in oncology patients, with a focus on epidemiology, pathophysiology, surveillance strategies, and management approaches.
Key Findings:
VEGF pathway inhibitors are a significant cause of therapy-induced hypertension in cancer patients, with implications for treatment outcomes.
Hypertension serves as both a modifiable cardiovascular risk factor and a potential biomarker of therapeutic efficacy, influencing treatment decisions.
Early detection and aggressive management of hypertension are crucial for improving both cardiovascular and oncologic outcomes.
Renin-angiotensin system inhibitors and calcium-channel blockers are effective first-line treatments, often used in combination for optimal control.
Interpretation:
VEGF inhibition leads to hypertension through mechanisms such as reduced nitric oxide availability, increased vascular stiffness, and renal effects, necessitating structured monitoring and management to mitigate cardiovascular risks.
Limitations:
The review may not encompass all potential cardiovascular toxicities associated with cancer therapies, which could affect comprehensive patient care.
Limited long-term data on the effects of hypertension management on overall cancer outcomes may hinder the development of best practices.
Conclusion:
Structured blood pressure management is essential in oncology care to optimize therapeutic benefits while minimizing cardiovascular risks, emphasizing a multidisciplinary approach.
by Nicolas L. Palaskas, Jung Hyun Kim, Silvia Fernanda López Moreno, Bernardo Casso-Chapa, Noah I. Beinart, Nnenne Nnanna, Keila Carolina Ostos Mendoza, Anita Deswal, Syed Wamique Yusuf, Efstratios Koutroumpakis, Jun-ichi Abe, Michael S. Ewer
